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Methotrimeprazine-induced Corneal Deposits and Cataract 
Revealed by Urine Drug Profiling Test
Two schizophrenic patients who had been taking medication for a long period presented 
with visual disturbance of 6-month duration. Slit-lamp examination revealed fine, discrete, 
and brownish deposits on the posterior cornea. In addition, bilateral star-shaped anterior 
subcapsular lens opacities, which were dense, dust-like granular deposits, were noted. 
Although we strongly suspected that the patient might have taken one of the drugs of the 
phenothiazine family, we were unable to obtain a history of medications other than 
haloperidol and risperidone, which were taken for 3 yr. We performed a drug profiling test 
using urine samples and detected methotrimeprazine. The patient underwent surgery for 
anterior subcapsular lens opacities. Visual acuity improved in both eyes, but the corneal 
deposits remained. We report an unusual case of methotrimeprazine-induced corneal 
deposits and cataract in a patient with psychosis, identified by using the urine drug 
profiling test.
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CASE REPORT
Ophthalmology
INTRODUCTION
Phenothiazine was introduced in 1953 and was widely used in 
psychiatry in the 1960s for the chronic treatment of schizophre-
nia. By the 1970s, there was a 30% reduction in the hospitaliza-
tion of schizophrenics, which was attributed to the introduction 
of phenothiazines, especially chlorpromazine. However, despite 
its extremely effective antipsychotic properties and a low inci-
dence of extrapyramidal symptoms, the use of phenothiazines 
has significantly declined over the last decade owing to its ocu-
lar complications.
  Phenothiazine ocular toxicity affecting the cornea, conjunc-
tiva, and lens was first described by Greiner and Berry in 1964 
(1). Since then, numerous authors have described ocular mani-
festations of long-term phenothiazine therapy. It is hypothe-
sized that phenothiazines denature proteins when exposed to 
light; the proteins then become opacified and are deposited in 
the lens, corneal stroma, and conjunctiva (2, 3). These ocular 
changes persist even after discontinuation of the drug.
  There have been several case reports of chlorpromazine-in-
duced corneal deposits and cataracts; however, methotrime-
prazine-induced corneal deposits and cataracts are unusual 
and rare. Herein, we report the first cases, to our knowledge, of 
methotrimeprazine-induced corneal deposits and cataract.
CASE REPORTS
Case 1
A 48-yr-old man, who had been taking medication for schizo-
phrenia, presented with visual disturbance of 6-month dura-
tion (June 22, 2006). In a span of 10 yr, he had been hospitalized 
several times for psychiatric treatment and had been under 
outpatient observation. Slit-lamp examination revealed fine, 
discrete, and brownish deposits on the posterior cornea (Fig. 1A, 
B). In addition, bilateral star-shaped anterior subcapsular lens 
opacities, which were dense, dust-like granular deposits, were 
noted (Fig. 1C, D). Best-corrected visual acuity was 20/40 in the 
right eye and 20/50 in the left eye. Other ocular findings were 
normal. According to the information provided by his family 
doctor, the patient had received 3 mg of haloperidol (thioxan-
thene family) and 6 mg of risperidone (molindone family) per 
day for 3 yr. Although we strongly suspected that the patient 
might have taken one of the drugs of the phenothiazine family, 
we were unable to obtain a history of medications other than 
those mentioned above. We performed the Remedi HS drug 
profiling test (Bio-Rad Co., Hercules, CA, USA) by using urine 
samples and detected methotrimeprazine. Analyzing the medi-
cal history, we found that the patient had taken methotrimepra-
zine habitually by using prescriptions from a different doctor Kim ST, et al.  •  Methotrimeprazine-induced Corneal Deposits and Cataract
http://jkms.org   1689 DOI: 10.3346/jkms.2010.25.11.1688
for about 3 yr, whenever he suffered from any anxiety or discom-
fort. Methotrimeprazine-induced corneal deposits and cataract 
were diagnosed on the basis of the clinical and laboratory find-
ings. It was then decided that the patient should undergo sur-
gery for the anterior subcapsular lens opacities, and he subse-
quently underwent phacoemulsification with posterior cham-
ber foldable intraocular lens implantation in both eyes. Topical 
antibiotics and steroids were used for 4 weeks, with tapering of 
the steroids. Three years after the operation, visual acuity had 
improved to 20/20 in both eyes, but the corneal deposits re-
mained.
Case 2
In another case, a 28-yr-old woman, also being treated for men-
tal retardation, hysteria, and nervous ticks, had been experienc-
ing visual disturbance for over a period of 4 months (Jan 12, 2009). 
Previously, she had been hospitalized and received outpatient 
care for these psychiatric illnesses for 4 yr. Slit-lamp examina-
tion revealed fine, discrete, and brownish deposits on the pos-
terior cornea (Fig. 2A, B). In addition, bilateral star-shaped an-
terior subcapsular lens opacities, which were dense, dust-like 
granular deposits, were noted (Fig. 2C, D). Visual acuity was 
20/50 in both eyes. Other ocular findings were normal. The pa-
tient was treated with 9 mg of haloperidol (thioxanthene fami-
ly), 300 mg of valproic acid, 1 mg of benztropine, 50 mg of tra-
zodone, and 2.5 mg of diazepam. After diazepam was discon-
tinued, she was given 15 mg of haloperidol, 400 mg of valproic 
acid, 1 mg of benztropine, and 1 mg of risperidone (molindone 
family), accordingly. At that time, we strongly suspected that 
the patient was taking a drug from the phenothiazine family, 
but we could not find any evidence of such use. However, we 
did detect methotrimeprazine in her body by using the Remedi 
HS drug profiling system (Bio-Rad Co., Hercules, CA, USA). 
Analyzing the medical history, we discovered that the patient 
habitually took methotrimeprazine over a period of 4 yr by ob-
taining prescriptions from various doctors, on suffering from 
any anxiety or discomfort. Furthermore, on the basis of clinical 
and laboratory results, methotrimeprazine-induced corneal 
deposits and cataract were detected.
Fig. 1. Slit lamp photographs (Case 1). It showed fine, discrete, and brownish deposits on the posterior cornea. (A) right eye, (B) left eye. It showed characteristic star-shaped 
deposits in the anterior sub-capsular area. (C) right eye, (D) left eye.
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DISCUSSION
Phenothiazines, such as chlorpromazine or methotrimepra-
zine, have been widely used for the treatment of mental diseas-
es after being introduced to the psychiatric clinics in 1953, and 
many studies have been conducted on the side effects of over-
dose and their complications (2-4). Methotrimeprazine is used 
for the treatment of psychosis, particularly in schizophrenia and 
manic phases of bipolar disorder. It should never be used in the 
treatment of agitated depressions because this drug increases 
agitation through the side effect of akathisia. Methotrimeprazine 
is also used in lower doses for the treatment of nausea. Long-
term medication of phenothiazine accumulates 50 times higher 
blood concentration in the ocular tissue in comparison to that 
of other tissues of the body (5). In 1964, Greiner and Berry (1) 
first described their findings on 70 patients who received long-
term medication of chlorpromazine (phenothiazine family), 
reporting that brown granular pigmentation occurred in the pa-
renchyma of the cornea and a central star-shaped opacity de-
Fig. 2. Slit lamp photographs (Case 2). It showed fine, discrete, and brownish deposits on the posterior cornea. (A) right eye, (B) left eye. It showed characteristic star-shaped 
deposits in the anterior sub-capsular area. (C) right eye, (D) left eye.
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veloped in the center of anterior capsular lens. Especially, many 
studies were conducted on the correlation between phenothi-
azine and lens opacity. McCarty et al. (6) reported that ratio of 
anterior capsular opacity in cataract patients who did not receive 
phenothiazine medications was 0.2%, while the ratio was 26% 
for schizophrenia patients who received phenothiazine medi-
cation. Ruigomez et al. (7) conducted a study on the incidence 
rate of cataract of schizophrenia patients and control group sub-
jects. Although the incidence rate of cataract was higher in the 
control group than in the schizophrenic patients, the incidence 
rate of cataract in patients under long-term medication of over 
300 mg chlorpromazine (phenothiazine family) daily was 8.8 
times that of the control group. Rather than reporting schizo-
phrenia as a risk factor of cataract, the authors reported that 
long-term medication of phenothiazine increases the risk of 
cataract. It is believed that the clinical changes in the conjuncti-
va, cornea, and lens observed in patients who received a specif-
ic dosage of drugs belonging to the phenothiazine family could 
be attributed to an increase in the number of melanin cells as-Kim ST, et al.  •  Methotrimeprazine-induced Corneal Deposits and Cataract
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sociated with exposure of the eyes to ultraviolet rays and the ac-
cumulation of abnormal metabolites due to a phototoxic reac-
tion resulting from the photosensitization of chlorpromazine 
that is present in a high concentration in the eyes exposed to 
visible and ultraviolet rays. Further, mutual interaction with phe-
nothiazine probably caused excessive production and accumu-
lation of melanin or melanin analogs. There is a controversy re-
garding the toxic level of phenothiazine. Delong et al. (8) report-
ed in 1965 that changes in the eyes were rare when the total dos-
age of chlorpromazine was 500 mg, that the characteristic eye 
findings were generally observed in patients receiving a dosage 
of over 1,000 mg, and that these findings were observed in more 
than 90% of patients receiving a dosage of over 2,500 mg. Thaler 
et al. (9) reported in 1985 that if the psychiatric conditions may 
require a daily dosages exceeding 800 mg of chlorpromazine, 
pigmentation of lens can begins to occur within as early as 14 to 
20 months of treatment. Dosages consisting of 2,000 mg of chlor-
promazine daily have caused lenticular changes within as early 
as only 6 months of therapy. As the dosage increased, changes 
in the eyes became more distinct and such changes continued 
after stopping the medication. Lal et al. (10) conducted a study 
on 15 patients with pigmentation in the skin and corneal endo-
thelium due to long-term usage of phenothiazine by replacing 
phenothiazine with other neuroleptics (haloperidol, levomepro-
mazine, trifluoperazine, and thioproperazine). They reported 
that ocular changes usually persist after the administration of 
the drug is stopped, but skin pigmentation can be reversible. 
They reported that mechanisms of pigmentation of the skin and 
cornea might be different from each other. 
  Although we strongly suspected that the patients in these 
cases might have taken one of the drugs of the phenothiazine 
family, we were unable to obtain a history of medications other 
than haloperidol and risperidone. We performed the Remedi 
HS drug profiling test (Bio-Rad Co., Hercules, CA, USA) by us-
ing urine samples and detected methotrimeprazine. The Reme-
di HS drug profiling system used automated, high-performance 
liquid chromatography to identify the presence of antipsychotic 
and anaesthetic drugs for the confirmatory urinalysis. The sen-
sitivity and specificity were calculated over 80% both in litera-
ture (11). There have been several case reports of chlorproma-
zine-induced corneal deposits and cataract; however, meth-
otrimeprazine-induced corneal deposits and cataracts are un-
usual, and identification by means of a urine drug profiling test 
are even rare.
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